Compounds > 2-(hydroxymethyl)anthraquinone
Page last updated: 2024-11-06

2-(hydroxymethyl)anthraquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(hydroxymethyl)anthraquinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID87014
CHEMBL ID21049
CHEBI ID28649
SCHEMBL ID41511
MeSH IDM0209010

Synonyms (34)

Synonym
brn 2120452
ccris 3522
anthraquinone, 2-(hydroxymethyl)-
einecs 241-274-3
9,10-anthracenedione, 2-(hydroxymethyl)-
2-(hydroxymethyl)-9,10-anthraquinone
2-(hydroxymethyl)anthracene-9,10-dione
CHEBI:28649 ,
2-(hydroxymethyl)anthraquinone
17241-59-7
2-hydroxymethylanthraquinone
anthraquinone-2-methanol
2-(hydroxymethyl)anthraquinone, 97%
CHEMBL21049
2-hydroxymethyl-anthraquinone
A811412
4-08-00-02607 (beilstein handbook reference)
FT-0608819
AKOS015856505
2-hydroxymethyl-9,10-anthracenedione
SCHEMBL41511
2-hydroxymethyl-9,10-anthraquinone
2-(hydroxymethyl)anthra-9,10-quinone #
mfcd00001236
DTXSID10169278
AS-63881
2-(hydroxymethyl)-9,10-dihydroanthracene-9,10-dione
CS-0131104
HY-N7502
J-010816
9,10-anthracenedione,2-(hydroxymethyl)
BCP24351
Q27103810
PD167284
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
anthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1867248Antibacterial activity against multidrug resistant Helicobacter pylori JRES00015 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method
AID1867247Antibacterial activity against multidrug resistant Helicobacter pylori HP159 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method
AID67634Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
AID1867246Antibacterial activity against multidrug resistant Helicobacter pylori G27 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method
AID231332Ratio of toxicity in areobic conditions to hypoxic condition of EMT6 cells1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
AID67635Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.90 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		1.9510mitomycinalkylating agent;
antineoplastic agent
2-methylanthraquinone
2-methylanthraquinone: form Morinda officinalis How.. 2-methylanthraquinone : An anthraquinone that is 9,10-anthraquinone in which the hydrogen at position 2 is substituted by a methyl group.		2.3820anthraquinone
methotrexate
[no description available]		1.9810dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9810L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		01.9810
Cancer of Prostate
[description not available]		01.9810
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9810
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9810